Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2200

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

$
0
0
Novo Nordisk said its highly anticipated Phase 3 readout showed that CagriSema only managed 22.7% weight loss at 68 weeks, failing to hit the 25% benchmark the company, investors and analysts were seeking. The result ...

Viewing all articles
Browse latest Browse all 2200

Trending Articles